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Renal fibrosis is the inevitable consequence of an excessive
accumulation of extracellular matrix that occurs in virtually
every type of chronic kidney disease. The pathogenesis of
renal fibrosis is a progressive process that ultimately leads to
end-stage renal failure, a devastating disorder that requires
dialysis or kidney transplantation. In a simplistic view, renal
fibrosis represents a failed wound-healing process of the
kidney tissue after chronic, sustained injury. Several cellular
pathways, including mesangial and fibroblast activation as
well as tubular epithelial–mesenchymal transition, have been
identified as the major avenues for the generation of the
matrix-producing cells in diseased conditions. Among the
many fibrogenic factors that regulate renal fibrotic process,
transforming growth factor-b (TGF-b) is one that plays a
central role. Although defective matrix degradation may
contribute to tissue scarring, the exact action and
mechanisms of the matrix-degrading enzymes in the injured
kidney have become increasingly complicated. Recent
discoveries on endogenous antifibrotic factors have evolved
novel strategies aimed at antagonizing the fibrogenic action
of TGF-b/Smad signaling. Many therapeutic interventions
appear effective in animal models; however, translation of
these promising results into humans in the clinical setting
remains a daunting task. This mini-review attempts to
highlight the recent progress in our understanding of the
cellular and molecular pathways leading to renal fibrosis, and
discusses the challenges and opportunities in developing
therapeutic strategies.
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Renal fibrosis, characterized by glomerulosclerosis and
tubulointerstitial fibrosis, is the final common manifestation
of a wide variety of chronic kidney diseases (CKD).
Irrespective of the initial causes, progressive CKD often
results in widespread tissue scarring that leads to the
complete destruction of kidney parenchyma and end-stage
renal failure, a devastating condition that requires dialysis or
kidney replacement.1 The pathogenesis of renal fibrosis is, in
essence, a monotonous process that is characterized by an
excessive accumulation and deposition of extracellular matrix
(ECM) components. In this context, the fundamental
questions are what types of cells produce a large amount of
ECM proteins under pathologic conditions, and how are they
regulated. A better understanding of these issues is not only
imperative for elucidating the pathogenic mechanism of
CKD, but may also provide novel insights into developing
new therapeutic strategies. Over the past several years,
significant progress has been made in our understanding of
the cellular and molecular mechanisms of renal fibrosis.2,3 In
this article, I attempt to provide a concise review of recent
advances on several issues in the pathogenesis and ther-
apeutics of chronic renal fibrosis.
CELLULAR EVENTS IN RENAL FIBROGENESIS: IT TAKES A
VILLAGE
The pathologic findings of renal fibrosis are often described
as glomerulosclerosis, tubulo-interstitial fibrosis, inflamma-
tory infiltration, and loss of renal parenchyma characterized
by tubular atrophy, capillary loss, and podocyte depletion
(Figure 1). The underlying cellular events leading to
these histologic presentations are even more complicated;
they include mesangial and fibroblast activation, tubular
epithelial to mesenchymal transition (EMT), monocyte/
macrophage, and T-cell infiltration, and cell apoptosis.
Although many in vitro studies emphasize the importance
of one particular cellular event such as fibroblast activation,
it should be kept in mind that no single type of cell in
isolation is capable of initiating and sustaining a full scale
of renal fibrosis. Renal fibrogenesis clearly necessitates
the participation and interaction of many types of
kidney resident and infiltrated cells. In this sense, it takes a
‘village’ to develop fibrotic lesions in an otherwise healthy
kidney.
http://www.kidney-international.org m i n i r e v i e w
& 2006 International Society of Nephrology
Received 8 September 2005; accepted 19 September 2005
Correspondence: Y Liu, Department of Pathology, University of Pittsburgh,
S-405 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, Pennsylvania
15261, USA. E-mail: liuy@upmc.edu
Kidney International (2006) 69, 213–217 213
The current model of renal fibrogenesis is one similar
to the wound-healing response to injury.2,4 After the initial
injury, the affected kidney tissues undergo a series of events
in an attempt to repair and recover from the damage. These
processes include kidney resident cell activation, which leads
to the production and secretion of proinflammatory
cytokines. The gradients of chemotactic cytokines provide a
directional signal for guiding the infiltration of inflammatory
monocytes/macrophages and T cells to the injured sites.
Depending on the etiology of renal injury, glomerular or
interstitial infiltrated inflammatory cells become activated,
and produce injurious molecules such as reactive oxygen
species, as well as fibrogenic and inflammatory cytokines.
These, in turn, stimulate mesangial cells, fibroblasts, and
tubular epithelial cells to undergo phenotypic activation or
transition and produce a large amount of extra cellular
matrix (ECM) components. Normal and novel forms of ECM
proteins are then deposited in the extracellular compartment,
and they are often crosslinked and become resistant to
degradation. Continuous deposition of ECM results in
fibrous scars and distorts the fine architecture of kidney
tissues, leading to the collapse of renal parenchyma and the
loss of kidney function. According to the sequence of these
destructive events, the pathogenesis of renal fibrosis can be
divided into several distinctive phases.2 However, it should be
stressed that renal fibrogenesis is a dynamic process in which
many of these events occur simultaneously, often in a
mutually stimulating fashion.
In view of its direct relevance to matrix accumulation,
activation of the matrix-producing effector cells is generally
regarded as a central event in renal fibrogenesis. Reliant on
the nature and sites of injury, glomerular mesangial cells,
interstitial fibroblasts, and tubular epithelial cells are the
major fibrogenic cells in the injured kidney, although other
cells, including bone marrow-derived cells, also play a role.
Myofibroblastic activation of mesangial cells and fibroblasts
is an early fibrogenic response after injury, whereas tubular
EMT often occurs in a delayed fashion. Recently, the
pathologic significance of tubular EMT in renal fibrosis has
become increasingly recognized.5,6 The hallmarks of mesan-
gial and fibroblast activation, as well as tubular EMT, are
de novo expression of a-smooth muscle actin, a contractile
protein normally restricted to perivascular smooth muscle
cells in vivo, and overproduction of the interstitial matrix
components such as type I and type III collagen and fibronectin.
What causes the difference between a healthy wound-
healing and fibrotic response remains a fascinating question.
One obvious distinction is the duration of the injury. An
acute, transient renal injury may trigger similar responses to
those in CKD, including inflammatory infiltration, secretion
of fibrogenic factors, and fibroblast activation, but the
damage is eventually repaired via tubular regeneration and
matrix remodeling, and tissue structure and function are
finally restored. As the duration of injury prolongs, wounded
tissues react in an imprudent way, leading to a maladaptation
that is characterized by the overproduction of the ECM that
causes fibrous scar. It is ambiguous why the same tissue
interprets the injurious signal differently in acute versus
chronic conditions. One potential explanation could be that
in the chronic situation after repeated injury, the fibrogenic
signal is continuously present and increasingly amplified,
owing to the progressive loss of the Smad antagonists.7 The
intensified fibrogenic signal not only stimulates fibroblast
activation in a manner akin to wound-healing, but also
initiates tubular EMT, a critical event that leads to the
destruction of renal parenchyma, with no way to return when
left untreated. In this sense, tubular EMT is a unique cellular
event that distinguishes a fibrogenic consequence in CKD
from a reparative injury response after acute insult, and
thereby determines the divergent fates of the kidney when
afflicted with a transient or sustained injury.
KEY MOLECULAR PATHWAY IN RENAL FIBROGENESIS: IT IS
THE SMAD WORLD
One of the central issues in renal fibrosis is to identify the key
molecular pathway leading to fibrogenic cell activation.
Although more than a dozen different fibrogenic factors
have been documented, including various cytokines and
hormonal, metabolic, and hemodynamic factors, it is widely
accepted that transforming growth factor-b (TGF-b) and its
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Figure 1 | A simplified scheme depicts the major pathologic findings, cellular events and key signaling mediators in renal fibrosis.
Multiple cellular events and molecular mediators participate and interact in concert in renal fibrogenesis, often in a mutually stimulating
manner. Arrows with broken lines indicate mutual interactions, whereas arrows with solid line denote activation.
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downstream Smad signaling play an essential role. Through
intensive investigations over the last decade, much has
been learned about the importance of TGF-b in tissue fibrosis
in general, and renal fibrosis in particular.8,9 Upregulation of
TGF-b is a universal finding in virtually every type of CKD,
both in animal models and in humans. In vitro, TGF-b as a
sole factor can stimulate mesangial cells, interstitial fibro-
blasts, and tubular epithelial cells to undergo myofibroblastic
activation or transition, to become matrix-producing fibro-
genic cells. Expression of exogenous TGF-b, either via gene
delivery in vivo or in transgenic mice, causes renal fibrosis.
Conversely, inhibition of TGF-b by multiple strategies
suppresses renal fibrotic lesions and prevents progressive loss
of kidney function. TGF-b induction also appears to be a
convergent pathway that integrates, directly or indirectly, the
effects of many other fibrogenic factors. Some of these, such
as angiotensin II and high glucose, act as an upstream TGF-b
inducer, whereas others such as connective tissue growth
factor work as its downstream effector.
The TGF-b signal is transduced through its cell
membrane type I and type II serine/threonine kinase
receptors.8 Receptor activation triggers the phosphorylation
and activation of its downstream signaling mediators, Smad2
and Smad3. Phosphorylated Smad2/3 bind to common
partner Smad4, and subsequently translocate into the nuclei,
where they control the transcription of TGF-b-responsive
genes. The TGF-b/Smad signaling is regulated at both
prereceptor and postreceptor stages through multiple levels
of modulation, which include the TGF-b gene expression,
latent TGF-b activation, its receptor expression, and post-
receptor Smad signaling. In the fibrotic kidney, a multitude
of mechanisms lead to a hyperactive TGF-b/Smad signaling.
Induction of TGF-b expression is one of them. Another is an
enhanced post-translational activation of TGF-b protein and
its release from latent complexes. The receptors for TGF-b are
also induced in diseased kidney.
Smad signaling in normal kidney is tightly constrained by
a family of proteins known as Smad transcriptional
corepressors, which include SnoN, Ski, and TGIF. Through
various mechanisms, these Smad antagonists effectively
confine Smad-mediated gene transcription, thereby safe-
guarding the tissue from unwanted TGF-b response. We
recently demonstrate that SnoN and Ski are progressively
diminished in the fibrotic kidney, suggesting that the loss of
Smad antagonists is an important mechanism that amplifies
the TGF-b signal.7 It is conceivable that the TGF-b/Smad
signal in the fibrotic kidney is transduced in such a way
without any constraint and is perhaps out of control, a
scenario very much similar to the loss of tumor suppressor
genes during tumorigenesis.
Not surprisingly, tremendous effort has been made to
inhibit TGF-b action in an attempt to hamper the
progression of renal fibrosis. Over the years, many novel
approaches have been tested, which include antisense
inhibition of TGF-b expression, neutralizing anti-TGF-b
antibody, soluble TGF-b receptor, or blockade of TGF-b
activation by decorin.8–10 A new strategy in development is to
use specific small molecule TGF-b receptor inhibitors. These
therapeutic interventions generally result in a different
spectrum of improvement of kidney structure and function
in animal models. However, translation of these results into
humans still remains a daunting task. Part of the reason is
related to the inherent difficulties associated with some of the
methodologies; for instance, it poses a great challenge to
achieve a meaningful antisense inhibition of TGF-b expres-
sion in the human kidney using current technology. But
more importantly, we still do not know with great certainty
whether long-term inhibition of TGF-b is an optimal
approach to the therapy of renal fibrosis, in light of the fact
that TGF-b is also an anti-inflammatory cytokine. As
inflammation is a major pathologic finding that is implicated
in the onset and progression of CKD, one should be cautious,
that long-term inhibition of TGF-b in humans may incite
inflammation, thereby possessing adverse consequence. After
all, mice with TGF-b1 deficiency die of massive inflamma-
tion. Accordingly, a recent report also shows that transgenic
mice with overexpression of TGF-b1 are actually protected
from developing renal fibrotic pathology, primarily through
its anti-inflammation activity.11
The profibrotic and anti-inflammatory properties of TGF-b
pose a dilemma for the therapeutic application of TGF-b
inhibition. To circumvent this problem, several strategies are
being developed to target the TGF-b downstream effectors or
the signaling that mediates its fibrogenic action. In this area,
suppression of connective tissue growth factor expression or
activity is one option. Another approach includes inhibition
of Smad signaling through the delivery of inhibitory
Smad7.12
MATRIX-DEGRADING ENZYMES IN RENAL FIBROGENESIS: IT IS
MORE THAN A FEW CUTS
Matrix homeostasis in normal tissues is a balance between
matrix production and its degradation. It is generally
believed that the excessive matrix accumulation seen in
fibrotic kidney results from both overproduction of matrix
components and defects in its degradation. This notion is
supported by many observations that plasminogen activator
inhibitor-1 and tissue inhibitor of matrix metalloproteinase-1
are often upregulated in a diseased kidney. Renal tissue
produces a number of proteases, in which the plasminogen/
plasmin and matrix metalloproteinase (MMP) systems
constitute a proteolytic network that is capable of degrading
all components of matrix proteins.
Given their proteolytic ability, matrix-degrading enzymes
are historically considered to reduce matrix accumulation,
thereby attenuating renal fibrosis after injury. However,
recent genetic studies using knockout mice have painted a
different and complex picture of the function of these
proteins in relation to fibrotic lesions in vivo. We report that
ablation of tissue-type plasminogen activator (tPA) actually
protects the kidney from developing interstitial fibrosis in
obstructive nephropathy; and more interestingly, this seems
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to have little to do with its proteolytic activity.13 The
pathogenic effect of tPA in obstructive nephropathy primarily
depends on its ability to induce MMP-9 gene expression.
Increased MMP-9 disrupts the integrity of tubular basement
membrane, which leads to the promotion of tubular EMT.
Further investigations reveal that tPA is able to bind to the
cell membrane receptor, low-density lipoprotein receptor-
related protein-1, induces its phosphorylation on tyrosine
residues, triggers intracellular signal transduction, and trans-
activates MMP-9 gene expression in renal interstitial
fibroblasts. This mode of action elicited by tPA resembles
that of a typical cytokine, a signaling protein that transduces
an extracellular signal into a cellular response across the
plasma membrane. Thus, it is tempting to postulate that, in
addition to its protease activity, tPA may function as a
cytokine.
Plasmin, a serine protease that can directly degrade matrix
proteins and activate MMPs, is also thought to be beneficial
in reducing renal fibrosis. However, knockout of the
plasminogen gene does not aggravate the fibrotic lesions
after ureteral obstruction. Instead, mice lacking plasmin
display a reduced collagen accumulation, suggesting a
significant pathogenic effect of this enzyme.14 Besides serine
proteases, studies on MMPs also reveal some surprising
findings. MMP-2 is found to be necessary and sufficient to
induce tubular EMT in vitro.15 Transgenic mice with over-
expression of MMP-2 display fibrotic lesions. A recent study
also demonstrates that MMP-3 induces Rac1 expression,
which causes an increase in cellular reactive oxygen species
and promotes EMT.16 Together, it becomes increasingly
obvious that we should no longer view the ‘matrix-degrading
enzymes’ as simple proteases. Some of these enzymes can
activate intracellular signaling, thereby having the potential
to elicit a wide range of cellular activities.
These new findings will undoubtedly change our concep-
tion of the function of the matrix-degrading enzymes in renal
fibrosis. Previous assumptions about matrix proteases in
renal fibrogenesis appear to be overly simplistic. The effect of
these enzymes probably depends on the nature and etiologies
of the diseases as well. In addition, their function may vary
dramatically in different stages during the course of disease
progression. Given so many uncertainties, it is premature to
predict the therapeutic usefulness of the matrix-degrading
enzymes or their inhibitors in renal fibrosis.
ENDOGENOUS ANTIFIBROTIC FACTORS AND FIBROSIS
THERAPY: IT IS ALL ABOUT THE BALANCES
Ancient Chinese medicine has taught us that a healthy state
in human body depends on the delicate balance between Yin
and Yang. Departure from this balance will lead to disastrous
consequences and illness. Guided by this principle, the
presence of fibrogenic factors almost certainly predicts that
there have to be some antagonists that counteract their
action. Indeed, recent studies have identified endogenous
antifibrotic factors, particularly hepatocyte growth factor
(HGF) and bone morphogenetic protein-7 (BMP-7), which
can precisely antagonize the fibrogenic action of TGF-b.
Therefore, restoration of the balance between pro- and
antifibrotic signaling could serve as a guiding principle for
designing rational therapeutic strategies. In this regard,
inhibition of profibrotic TGF-b/Smad signaling is only half
the equation. Another approach is to increase the antifibrotic
factors in the diseased kidney.
HGF has recently emerged as a potent antifibrotic factor in
the kidney, as well as in other organs. It possesses a
remarkable ability to promote tissue repair and regeneration
after various injuries. In many aspects, the effects of HGF and
TGF-b on kidney cells are exactly opposite. In vitro, HGF
effectively inhibits the TGF-b-mediated myofibroblastic
activation from glomerular mesangial cells and interstitial
fibroblasts, and blocks tubular EMT.17 Dissection of the
signal pathways has provided novel insights into the
molecular mechanisms of HGF action. We demonstrate that
HGF blocks Smad2/3 nuclear translocation in interstitial
fibroblasts, upregulates Smad transcriptional corepressor
TGIF via protein stabilization in mesangial cells, and induces
SnoN expression in tubular epithelial cells.18 Therefore, albeit
initially divergent, HGF signaling in different kidney cells is
converged to a common pathway that specifically targets
Smad signaling. Consistently, administration of exogenous
HGF or its gene ameliorates renal fibrosis and preserves
kidney functions in a wide variety of animal models of CKD,
including obstructive nephropathy, remnant kidney, diabetic
nephropathy, and chronic allograft nephropathy.19
BMP-7 is a member of the TGF-b superfamily that
counteracts the fibrogenic action of TGF-b. Its expression is
often downregulated in the fibrotic kidney. Supplementation
with exogenous BMP-7 suppresses renal fibrosis in experi-
mental renal diseases. In vitro, BMP-7 antagonizes TGF-b and
inhibits tubular EMT.20 Although the molecular details
remain to be elucidated, inhibition of the fibrogenic Smad
signaling is believed to play a central role in mediating the
antifibrotic action of BMP-7.4,20
Despite the remarkable therapeutic efficacy of HGF and
BMP-7 in animal models, translation of these promising
results into humans is waiting to happen. At this stage, it
appears that there are sufficient preclinical data to warrant
clinical trials to test the safety and efficacy of the antifibrotic
factors on patients with chronic renal insufficiency. In spite
of many challenges, these clinical trials will offer exciting
opportunities for the ultimate test of the usefulness and
efficacy of antifibrotic factors in the treatment of human
CKD.
Induction of endogenous antifibrotic factor expression
could be another strategy in combating renal fibrosis. In this
respect, we have recently found that many renoprotective
agents, such as peroxisome proliferator-activated receptor-g
agonists, 9-cis-retinoic acid, and 1,25-dihydroxyvitamin D3,
induce HGF gene expression in mesangial cells and inter-
stitial fibroblasts. Therefore, induction of antifibrotic HGF
expression may be a convergent pathway leading to renal
protection. Consistent with this notion, ablation of HGF
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receptor in mesangial cells abolishes the antifibrotic effects of
these renoprotective agents. Hence, as an alternative path to
direct administration of HGF itself, upregulation of endo-
genous HGF expression by small molecule inducers may offer
a practically attractive strategy for the treatment of renal fibrosis
in clinical setting.
CONCLUSION
The process of renal fibrosis, in which multiple cellular events
and molecular mediators participate and interact in concert,
is enormously complicated. Despite these complexities,
several important issues have recently come to light. In
comparison to healthy wound healing, tubular EMT is a
unique event that occurs in the fibrotic tissue after chronic
injury, which may set the injured kidney in motion to scar
formation. It also becomes apparent that induction and
activation of TGF-b/Smad signaling are critical for initiating
a fibrogenic response; and equally important is the loss of the
Smad antagonists, which could render the fibrogenic
signaling out of control. Finally, the identification of
endogenous antifibrotic factors has provided us with
unprecedented opportunities for therapeutic interventions
of renal fibrosis. In view of the impressive efficacy of
antifibrotic factors in attenuating experimental renal fibrosis,
it is hoped that the translation of these studies into humans
will result in improved therapeutics for patients with chronic
renal insufficiency.
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